Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Chimeric Therapeutics - Successful completion of Institutional Entitlement Offer (ASX:CHM)

Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) refers to its announcement of 21 February 2022 in relation to an equity raising being undertaken by the Company by way of an accelerated...read more

Chimeric Therapeutics - Prospectus (ASX:CHM)

Accelerated non-renounceable pro rata entitlement offer of 1 New Share for every 3.15 Existing Shares (and one New Option for every New Share issued) at an offer price of $0.17 per New Share to rais...read more

Chimeric Therapeutics - Appendix 3B (ASX:CHM)

To view the appendix, download the attached PDF.

Chimeric Therapeutics - Entitlement Offer to raise approximately $18.1 million (ASX:CHM)

Key Points -- Accelerated non-renounceable entitlement offer to raise approximately $18.1 million (before costs) -- Offer price of $0.17 per new share, a 15% discount to the closing price of Chi...read more

Chimeric Therapeutics - Trading Halt (ASX:CHM)

The securities of Chimeric Therapeutics Limited (‘CHM’) will be placed in trading halt at the request of CHM, pending it releasing an announcement regarding the outcome of the institutio...read more

Chimeric Therapeutics - Encouraging data from 2nd dose cohort in CLTX CAR T trial (ASX:CHM)

-- Encouraging safety for dual routes (intratumoral and intraventricular) of CLTX chimeric antigen receptor (CAR) T cell administration as therapy was generally well tolerated -- Initial signal for...read more

Chimeric Therapeutics - Sponsored Research Agreement with University of Pennsylvania (ASX:CHM)

-- Chimeric has executed a three-year Sponsored Research Agreement with the University of Pennsylvania, for research to be conducted in the laboratory of Xianxin Hua, MD, PhD -- The research will f...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the ASX leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31 Decem...read more

Chimeric receives US patent covering CLTX CAR technology (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and the ASX leader in cell therapy, is pleased to announce that the United States Patent and Trademark ...read more

Chimeric Therapeutics - Transformative Portfolio Expansion Presentation (ASX:CHM)

To view the presentation, download the attached PDF.

Chimeric Therapeutics - Webinar CHM Transforms Portfolio (ASX:CHM)

Chimeric has obtained the exclusive option to license the CORE-NK platform, a Clinically validated, Off the shelf, Robust, Enhanced Natural Killer cell platform from Case Western Reserve University...read more

Chimeric Therapeutics - CLTX CAR T data shows regional control of tumour recurrence (ASX:CHM)

CLTX CAR T clinical data highlighted in Keynote presentation on November 20th 75% disease control rate seen at lowest dose level with up to 8 weeks of durability Tumour recurrence prevented at ...read more

Chimeric Therapeutics - CLTX CAR T presents positive initial Phase 1 clinical data (ASX:CHM)

75% disease control rate seen at lowest dose level of CLTX CAR T cells CLTX CAR T was generally well tolerated with no dose limiting toxicities Persistence of CLTX CAR T cells shown throughout ...read more

First milestone on path to CDH17 CAR T clinical trial (ASX:CHM)

Phase 1 plasmid manufacturing commenced Phase 1 clinical trial for neuroendocrine & colorectal tumors planned for 2022 Positions Chimeric to have a minimum of two Phase 1 trials underway du...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

To view the report, download the attached PDF.

Viewing: 61 - 75 of 154 Previous | Next